

Preliminary Results of Public Joint Shareholders Company

(Final Result Brief for the year ended 31 December 2022)

First - General Information :

Name of the company: Gulf Pharmaceutical Industries PSC (Julphar)

Date Establishment: 1980

Paid up capital: 1,155,227,811

Subscribed capital: 1,155,227,811

Authorized capital: 1,155,227,811

Chairman of the Board: Sheikh Saqer Bin Humaid Al Qasimi

Name of the external auditor: M/s Ernst & Young

Mailing address: P.O. Box 997

Tel: 009717 2461461

Fax: 009717 2462462

E – mail: julphar@emirates.net.ae

Second - Preliminary Results (000 AED) :

	<u>2022</u>	<u>2021</u>
Total Assets	2,381,700	2,426,300
Shareholders Equity	915,300	956,700
Revenues	1,621,300	1,143,200
EBITDA for the period	156,600	164,800
Net Operating Profit	26,800	63,900
Net profit for the period	(11,700)	59,400
Earnings per share (fils per share)	(0.8)	5.6

Summary of the company's performance for the last fiscal year.

Julphar's revenue reached 1,621.3 mAED for the year 2022, an increase of 41.8% from previous year. The strong revenue growth was generated from continued market share increase in the Company's key markets including United Arab Emirates, the Kingdom of Saudi Arabia and several North African markets.

The Group's continued focus on operational performance resulted in EBITDA of 156.6 mAED (9.7% of net sales) and net operating profit of 26.8 mAED. This is a significant improvement over the adjusted Net Operating Profit of 2021 (-83 mAED) after considering the favorable one-off event of the vaccine business of previous year.

During the reported period, Julphar made significant progress in its efforts to invest in the product pipelines of its core business areas.

Julphar is committed to providing the most affordable and highest quality health care solutions in the MENA region.

The name of the chairman of the company or the authorized signatory	Sheikh Saqer Bin Humaid Al Qasimi
Signature and Date	14/02/2023

